GEN Exclusives

More »

GEN News Highlights

More »
Mar 12, 2008

Raven Inks Manufacturing Deal with CMC to Help Advance RAV 18 into the Clinic

  • Raven biotechnologies entered into an agreement under which CMC Icos Biologics will create a production cell line for Raven’s next IND candidate, RAV18. Raven is targeting  to file in 2009.

    The product is a humanized antibody targeting the ADAM9 protein on cells. ADAM9 is expressed on solid tumors and is thought to contribute to disease progression and metastasis.

    A number of carcinoma cell lines have been shown to amplify the gene for ADAM9 and to overexpress the protein. This overexpression has been reported in pancreatic, prostate, gastric, breast, and lung cancers.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?